Literature DB >> 31843598

Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis.

Rish K Pai1, Douglas J Hartman2, Claudia Ramos Rivers3, Miguel Regueiro4, Marc Schwartz3, David G Binion3, Reetesh K Pai5.   

Abstract

BACKGROUND & AIMS: We investigated correlations between histologic features of the colonic mucosa in patients with ulcerative colitis (UC) and clinical outcomes during a 3-year follow-up period.
METHODS: We obtained baseline biopsies from all colorectal segments (n = 889) from 281 patients with UC enrolled in a prospective study at a single center from 2009 through 2013. Biopsies were assessed in a blinded manner using validated histologic scoring systems (the Geboes score, Nancy histopathologic index, and Robarts histopathologic index). Clinical, endoscopic, and histologic data were collected and tested for correlations with systemic corticosteroid use, hospitalization, and colectomy within 3 years of the index colonoscopy.
RESULTS: We found histologic evidence of UC activity (Geboes score ≥ 2B.1) in biopsies from 182 patients (65%) and endoscopic evidence of UC activity in 149 patients (53%) (substantial agreement, κ = 0.60). Histologic features of UC activity were associated with increased rates of systemic corticosteroid use, colectomy, and hospitalization in the entire cohort (P < .05 for all) and associated with increased rates of systemic corticosteroid use in an analysis limited to patients in endoscopic remission (P < .001). In patients in endoscopic remission, only histologic activity was independently associated with use of systemic corticosteroids (multivariate odds ratio, 6.34; 95% CI, 2.20-18.28; P = .001). Similar results were seen when the entire cohort was analyzed. Compared with patients without histologic evidence of UC activity, patients with only a small number of mucosal neutrophils still had higher rates of systemic corticosteroid use (P < .001).
CONCLUSIONS: Histologic evidence of UC activity, including small numbers of neutrophils in the colonic mucosa, is the only factor independently associated with use of systemic corticosteroids. Complete resolution of neutrophil-associated inflammation should be a target for treatment of UC.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immune Cell; Inflammatory Bowel Diseases; Prognostic Factor; Therapy

Year:  2019        PMID: 31843598     DOI: 10.1016/j.cgh.2019.12.011

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  9 in total

1.  An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.

Authors:  Christopher Ma; Rocio Sedano; Ahmed Almradi; Niels Vande Casteele; Claire E Parker; Leonardo Guizzetti; David F Schaeffer; Robert H Riddell; Reetesh K Pai; Robert Battat; Bruce E Sands; Christophe Rosty; Marla C Dubinsky; Florian Rieder; Noam Harpaz; Maria T Abreu; Robert V Bryant; Gregory Y Lauwers; Richard Kirsch; Mark A Valasek; Eileen Crowley; William J Sandborn; Brian G Feagan; Rish K Pai; Vipul Jairath
Journal:  Gastroenterology       Date:  2021-02-19       Impact factor: 22.682

2.  PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis.

Authors:  Olga Maria Nardone; Alina Bazarova; Pradeep Bhandari; Rosanna Cannatelli; Marco Daperno; Jose Ferraz; Martin Goetz; Xianyong Gui; Bu Hayee; Gert De Hertogh; Mark Lazarev; Ji Li; Adolfo Parra-Blanco; Luca Pastorelli; Remo Panaccione; Vincenzo Occhipinti; Timo Rath; Samuel C L Smith; Uday N Shivaji; Gian Eugenio Tontini; Michael Vieth; Vincenzo Villanacci; Davide Zardo; Raf Bisschops; Ralf Kiesslich; Subrata Ghosh; Marietta Iacucci
Journal:  United European Gastroenterol J       Date:  2022-02-23       Impact factor: 4.623

3.  Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease.

Authors:  Corinna Lang-Schwarz; Abbas Agaimy; Raja Atreya; Christoph Becker; Silvio Danese; Jean-François Fléjou; Nikolaus Gaßler; Heike I Grabsch; Arndt Hartmann; Kateřina Kamarádová; Anja A Kühl; Gregory Y Lauwers; Alessandro Lugli; Iris Nagtegaal; Markus F Neurath; Georg Oberhuber; Laurent Peyrin-Biroulet; Timo Rath; Robert Riddell; Carlos A Rubio; Kieran Sheahan; Herbert Tilg; Vincenzo Villanacci; Maria Westerhoff; Michael Vieth
Journal:  Virchows Arch       Date:  2020-12-29       Impact factor: 4.064

4.  Inhibitor of Differentiation-2 Protein Ameliorates DSS-Induced Ulcerative Colitis by Inhibiting NF-κB Activation in Neutrophils.

Authors:  Jie Ren; Dong Yan; Yichun Wang; Jiaojiao Zhang; Min Li; Wancheng Xiong; Xueqian Jing; Puze Li; Weidong Zhao; Xiwen Xiong; Minna Wu; Genshen Zhong
Journal:  Front Immunol       Date:  2021-11-04       Impact factor: 7.561

5.  Validation of the 'Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn´s Disease.

Authors:  Corinna Lang-Schwarz; Miriam Angeloni; Abbas Agaimy; Raja Atreya; Christoph Becker; Theresa Dregelies; Silvio Danese; Jean-François Fléjou; Nikolaus Gaßler; Heike I Grabsch; Arndt Hartmann; Kateřina Kamarádová; Anja A Kühl; Gregory Y Lauwers; Alessandro Lugli; Iris Nagtegaal; Markus F Neurath; Georg Oberhuber; Laurent Peyrin-Biroulet; Timo Rath; Robert Riddell; Carlos A Rubio; Kieran Sheahan; Britta Siegmund; Herbert Tilg; Vincenzo Villanacci; Maria Westerhoff; Fulvia Ferrazzi; Michael Vieth
Journal:  J Crohns Colitis       Date:  2021-10-07       Impact factor: 9.071

6.  PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system.

Authors:  Xianyong Gui; Alina Bazarova; Rocìo Del Amor; Vincenzo Villanacci; Michael Vieth; Gert de Hertogh; Davide Zardo; Tommaso Lorenzo Parigi; Elin Synnøve Røyset; Uday N Shivaji; Melissa Anna Teresa Monica; Giulio Mandelli; Pradeep Bhandari; Silvio Danese; Jose G Ferraz; Bu'Hussain Hayee; Mark Lazarev; Adolfo Parra-Blanco; Luca Pastorelli; Remo Panaccione; Timo Rath; Gian Eugenio Tontini; Ralf Kiesslich; Raf Bisschops; Enrico Grisan; Valery Naranjo; Subrata Ghosh; Marietta Iacucci
Journal:  Gut       Date:  2022-02-16       Impact factor: 23.059

Review 7.  Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?

Authors:  Panu Wetwittayakhlang; Livia Lontai; Lorant Gonczi; Petra A Golovics; Gustavo Drügg Hahn; Talat Bessissow; Peter L Lakatos
Journal:  J Clin Med       Date:  2021-11-26       Impact factor: 4.241

8.  LCN2 as a Potential Diagnostic Biomarker for Ulcerative Colitis-Associated Carcinogenesis Related to Disease Duration.

Authors:  Fushun Kou; Yuan Cheng; Lei Shi; Jiajing Liu; Yuyue Liu; Rui Shi; Guiying Peng; Junxiang Li
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

9.  Endoscopy and histology in inflammatory bowel diseases patients: Complementary or alternatives?

Authors:  Ferdinando D'Amico; Alessandra Zilli; Gionata Fiorino
Journal:  United European Gastroenterol J       Date:  2022-01-22       Impact factor: 4.623

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.